{"id":"NCT04614948","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-12","primaryCompletion":"2023-06-18","completion":"2023-06-18","firstPosted":"2020-11-04","resultsPosted":"2024-10-09","lastUpdate":"2025-02-04"},"enrollment":31835,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.COV2.S","otherNames":["JNJ-78436735","Ad26COVS1","VAC31518"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ad26.COV2.S","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.","primaryOutcome":{"measure":"Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at Least 14 Days After the Second Vaccination","timeFrame":"From at least 14 days after second vaccination on Day 57 (Day 71) up to end of double blind phase (7.2 months)","effectByArm":[{"arm":"Double Blind Phase: Ad26.COV2.S","deltaMin":14,"sd":null},{"arm":"Double Blind Phase: Placebo","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":126,"countries":["United States","Belgium","Brazil","Colombia","France","Germany","Philippines","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["36113538"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":104,"n":15705},"commonTop":["Vaccination site pain(Solicited)","Fatigue(Solicited)","Headache(Solicited)","Myalgia(Solicited)","Nausea(Solicited)"]}}